Intravenous bevacizumab repackaged for intravitreal use: Making the sight-saving treatment saferAugust 10th 2022
Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.
ASRS 2022 in review: New data on DMO, AMD presented at this year's meetingJuly 19th 2022
The American Society of Retina Specialists held its 40th Annual Meeting in New York, New York, United States, from 13-16 July, 2022. While data was presented for all topics in retina, new revelations in age-related macular degeneration, diabetic retinopathy, and diabetic macular oedema dominated the conversation.
Hypersonic vitrectomy a novel technology for removing vitreousJune 29th 2022
Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Dr Sunir J. Garg explains how retinal surgeons can remove the vitreous gel with more efficiency.
Significance of the YOSEMITE and RHINE 2-year DMO clinical trial resultsJune 28th 2022
In the study, the faricimab molecule, which is a combined anti-Ang2 and anti-VEGF, performed better than the aflibercept drug in many different ways. Rishi P. Singh, MD, FASRS, summarizes some of these key findings.
Self-plugging microneedles may improve drug delivery in the eyeJune 27th 2022
In a recent study, investigators found preclinical evidence that this innovative, biodegradable microneedle, dip-coated with a therapeutic drug for release upon insertion into the eyeball, can also be equipped with a special hydrogel that simultaneously seals off the insertion hole.
Is retinal tissue preservation as important as decreased GA expansion in future therapies?June 23rd 2022
As novel therapies in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Dr Karl Csaky and Dr Fredrick Ferris III identified in 2007—Dr Csaky reinforces the importance of preserving the central retinal tissue.
Phase 1 trial finds at-home subcutaneous injection option safe, effective for the treatment of wet AMD, DMOJune 14th 2022
Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous anti-VEGF injection option in development for the treatment of wet AMD and DMO.